Amgen (AMGN) Tops Q1 EPS by 15c, Offers Guidance

Amgen (NASDAQ: AMGN) reported Q1 EPS of $4.25, $0.15 better than the analyst estimate of $4.10. Revenue for the quarter came in at $6.2 billion versus the consensus estimate of $6.07 billion.

GUIDANCE:

Amgen sees FY2022 EPS of $17.00-$18.00, versus the consensus of $17.63. Amgen sees FY2022 revenue of $25.4-26.5 billion, versus the consensus of $26.14 billion.

For earnings history and earnings-related data on Amgen (AMGN) click here.

You May Also Be Interested In

• FTC files amicus brief challenging Amgen's Enbrel patent acquisition
• Nordson Corp. (NDSN) Tops Q3 EPS by 16c; Offers Guidance
• ATRenew Inc (RERE) Tops Q2 EPS by 8c ; Offers Guidance